Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (22555)	1/18/2007 11:55:43 AM
From: Ian@SI	Read Replies (2) \| Respond to of 52153

Sounds like you're now agreeing with me. Big pharma isn't going to fund research into an already approved, available, inexpensive drug which shows some promising characteristics in the fight against cancer. ;-) I'm not spitting on/at/in big pharma research. To me it's just an obvious statement of fact. Publicly traded companies expect a ROI from R&D $ - regardless of which sector they serve. "But who's going to pay for the clinical trials ... it's $70 million to $100 million." listen man, if this stuff has a chance, then every cancer charity fund in the world would foot the bill for the clinical trials. Now, I'm not saying it won't work, but don't spit in the face of real research being done in the pharmaceutical industry.